Allegro, Senju team up to develop treatment of vascular eye diseases

Article

Senju acquired the rights to co-develop and market Allegro's integrin peptide therapy for intravitreal injection for vascular eye diseases such as AMD and diabetic macular edema.

San Juan Capistrano, CA, and Osaka, Japan-Allegro Ophthalmics LLC and Senju Pharmaceutical Co. Ltd. have entered into a collaboration and license agreement to develop and market Allegro’s Integrin Peptide Therapy in Japan. The pairing aims to improve the quality of life for patients at risk of blindness due to vascular eye diseases by establishing Integrin Peptide Therapy as the first-in-class treatment.

Under the terms of the agreement, Senju will acquire the rights to co-develop and market Allegro’s Integrin Peptide Therapy in Japan as an intravitreal injection for vascular eye diseases such as wet age-related macular degeneration and diabetic macular edema. In exchange for these rights, Senju has agreed to pay Allegro an 8-digit upfront license fee, additional development and sales milestone fees, and a percentage royalty on net sales.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
© 2025 MJH Life Sciences

All rights reserved.